---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016635"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:57:10.331401+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics Q2 2022 net loss $22.7M; revenue down $2.5M YoY

## Summary
- Net loss of $22.7M vs $15.2M in Q2 2021; R&D flat at $13.9M; G&A up to $8.2M.
- Revenue fell primarily due to Takeda agreement amendment; prior period had $1.8M PPP loan gain.
- Cash $104.7M as of June 30, 2022 (down from $133.5M Dec 2021); funds operations into Q1 2024.
- On track to start enrollment in PRISM4 Phase 3 CP101 trial in H2 2022; topline data expected H1 2024.
- PRISM-EXT results accepted for ACG 2022; FIN-211 IND submission on track for Q4 2022.

## SEC filing metadata
- accession: 0000950170-22-016635
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022016635/0000950170-22-016635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022016635/fnch-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016635
- JSON: https://secwatch.observer/filing/0000950170-22-016635.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.